Member access

4-Traders Homepage  >  Shares  >  Toronto Stock Exchange  >  Cardiome Pharma Corp.    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
02/24/2015 02/25/2015 02/26/2015 02/27/2015 03/02/2015 Date
12.2 12.25 12.15 12.15 12.5 Last
4610 1268 12740 2590 4837 Volume
-0.57% +0.41% -0.82% 0.00% +2.88% Change
Company
Cardiome Pharma Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of new therapies that will improve the health of patients around the world.Its product BrinavessTM approved in Europe and other territories for the rapid conversion of recent... 
Sector
Pharmaceuticals
Calendar
03/24Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp.
Trading Rating : Investor Rating :
More Ratings
Chart CARDIOME PHARMA CORP.
Duration : Period :
Cardiome Pharma Corp. Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Financials ( CAD)
Sales 2014 36,1 M
EBIT 2014 -13,7 M
Net income 2014 -16,8 M
Debt 2014 -
Yield 2014 -
Sales 2015 38,7 M
EBIT 2015 -12,5 M
Net income 2015 -13,1 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 5,74x
Capi. / Sales 2015 5,35x
Capitalization 207 M
More Financials
Latest news on CARDIOME PHARMA CORP.
2014 CARDIOME PHARMA : Enters Development And Commercialization Agreement With Edding..
2014 CARDIOME PHARMA : Enters Development and Commercialization Agreement with Edding..
2014 CARDIOME PHARMA : Enters Commercialization Agreement With Aspen For Brinavess In..
2014 CARDIOME PHARMA : Enters Commercialization Agreement with Aspen for BRINAVESS® i..
2014 CARDIOME PHARMA : Announces Positive Results from the BRINAVESS® Asia-Pacific Ph..
2014 CARDIOME PHARMA : Submits BRINAVESS® Reimbursement Dossier to Italian Authoritie..
2014 CARDIOME PHARMA : Reports Third Quarter 2014 Financial Results
2014 CARDIOME PHARMA : to Hold Third Quarter 2014 Financial Results Conference Call o..
More news
Sector news Biopharmaceuticals
06:00a BRISTOL MYERS SQUIBB : Hepatitis C cure rate of 97 per cent announced in study o..
05:50aDJMARKET SNAPSHOT : U.S. Stocks: Futures Retreat After Nasdaq Breaks Above 5,000
05:46a ASTRAZENECA : to collaborate with Cambridge Judge Business School
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF